Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Ocular Therapeutix, Inc. (OCUL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.43-9.94%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for OCUL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Stable CFO leadership | A supporting condition in Ocular Therapeutix, Inc.'s published investment case. The stated target is Permanent CFO in place through FY26. | Intact | CFO position becomes vacant or unstable during FY26 | CFO stable vs vacant target June 2026 news confirms Jason Robins appointed as permanent CFO, resolving interim status and meeting the stability target. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage growth story, not a proven earnings compounder, because the business is loss-making. The long-term thesis is in a watch state: key clinical and regulatory milestones are progressing, but recent financial performance is weak relative to peers.
OCUL is valued at a premium to peers, and the model points to a small expectations gap, with low confidence. The premium is attributed to the potential of its development programs; the evidence describes the valuation as justified, not as part of a broader stack of expensive valuation, weak fundamentals, and turbulence.
Near term, weak recent performance and the loss-making profile keep the risk elevated, though the evidence flags a low near-term miss risk and a quiet watch tier. Management is on track with the planned Q4 2026 AXPAXLI NDA submission and clinical trial milestones, while commercial launch preparations for 2027 remain on watch.
The multi-year thesis depends on the planned NDA submission, trial progress, and whether commercial readiness supports a potential 2027 launch. Near term, a guidance cut would be a negative signal; continued strength from healthcare bellwethers could support sector momentum, while weakening job growth could increase pressure on healthcare names.
Over the next 1 to 3 years, OCUL’s thesis has meaningful development and launch potential, but it remains dependent on execution amid weak financial performance and elevated risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Ocular Therapeutix, Inc.'s published investment case. The stated target is net loss less negative than $(88.6) million in FY26. |
| Intact |
| net loss worsens beyond $(88.6) million in FY26 |
Net income: $-78.763M FY2026-Q2; GAAP. Published target: net loss less negative than $(88.6) million in FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 3, 2026-78,763,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth of about 76% in FY26 | A primary condition in Ocular Therapeutix, Inc.'s published investment case. The stated target is >=75.9% YoY revenue growth. | Improving | YoY revenue growth falls below ~75.9% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.54 → $-1.48 · observed estimates
$0.12B → $0.10B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.54 | $120,348,620 | 4 / 11 |
| 2026-07-25 | $-1.44 | $120,358,761 | 6 / 8 |
| 2026-07-26 | $-1.54 | $120,348,620 | 4 / 11 |
| 2026-07-27 | $-1.44 | $120,359,670 | 6 / 8 |
| 2026-07-28 | $-1.54 | $120,348,620 | 4 / 11 |
| 2026-07-29 | $-1.54 | $120,348,620 | 4 / 11 |
| 2026-07-30 | $-1.54 | $120,348,620 | 4 / 11 |
| 2026-07-31 | $-1.44 | $120,359,670 | 6 / 8 |
| 2026-08-01 | $-1.44 | $120,359,670 | 6 / 8 |
| 2026-08-02 | $-1.48 | $120,348,620 | 5 / 11 |
| 2026-08-03 | $-1.44 | $120,359,670 | 7 / 8 |
| 2026-08-04 | $-1.48 | $112,420,070 | 4 / 11 |
| 2026-08-05 | $-1.49 | $100,743,398 | 6 / 8 |
| 2026-08-06 | $-1.48 | $112,374,620 | 4 / 11 |
| 2026-08-07 | $-1.49 | $100,660,064 | 6 / 8 |
| 2026-08-08 | $-1.47 | $102,501,890 | 5 / 11 |
| 2026-08-09 | $-1.45 | $102,489,540 | 5 / 11 |
| 2026-08-10 | $-1.45 | $102,489,540 | 5 / 11 |
| 2026-08-12 | $-1.49 | $100,660,064 | 6 / 8 |
| 2026-08-13 | $-1.49 | $100,660,064 | 6 / 8 |
| 2026-08-14 | $-1.49 | $100,660,064 | 6 / 8 |
| 2026-08-15 | $-1.49 | $100,660,064 | 6 / 8 |
| 2026-08-16 | $-1.49 | $100,660,064 | 7 / 8 |
| 2026-08-17 | $-1.49 | $100,660,064 | 7 / 8 |
| 2026-08-18 | $-1.49 | $100,660,064 | 7 / 8 |
| 2026-08-19 | $-1.49 | $100,660,064 | 7 / 8 |
| 2026-08-20 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-08-21 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-08-22 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-08-23 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-08-24 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-08-25 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-08-26 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-08-27 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-08-28 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-08-29 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-08-30 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-08-31 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-01 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-02 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-03 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-04 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-05 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-06 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-07 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-08 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-09 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-10 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-11 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-12 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-13 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-14 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-15 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-16 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-17 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-18 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-19 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-20 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-21 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-22 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-23 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-24 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-25 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-26 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-27 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-28 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-29 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-09-30 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-01 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-02 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-03 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-04 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-05 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-06 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-07 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-08 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-09 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-10 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-11 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-12 | $-1.47 | $100,620,390 | 7 / 9 |
| 2026-10-13 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-14 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-15 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-16 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-17 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-18 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-19 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-20 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-21 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-22 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-23 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-24 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-25 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-26 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-27 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-28 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-29 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-30 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-10-31 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-11-01 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-11-02 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-11-03 | $-1.48 | $100,361,810 | 8 / 9 |
| 2026-11-04 | $-1.48 | $100,361,810 | 8 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.